Reports Q2 revenue $31.7M, consensus $16.7M. Cash, cash equivalents and marketable securities as of June 30, 2025 were $366 million compared to $424 million at March 31, 2025. “Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our collective commitment to advancing care for women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics (SAGE). “As we work with Supernus to complete the transaction, we take pride in the progress made to date and remain focused on the important work of helping more patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Supernus announces expiration of HSR waiting period for Sage Therapeutics
- Sage Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
- Sage Therapeutics cutting over 330 jobs, Boston Globe reports
- Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts